View full meeting coverage »

Eyetube Meeting Coverage:

2018 ARVO Annual Meeting


Editorially Independent Content, Financially Supported by


Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Results From the STOMP-CSC Trial

  Channels: Retina | Posted 5/1/2018

Roger A. Goldberg, MD, MBA, shares first-time results from the randomized, double-masked, placebo-controlled STOMP-CSC clinical trial of short-term oral mifepristone for the treatment of central serous chorioretinopathy.

Central serous chorioretinopathy, CSC

1 / 13 Series: 2018 ARVO Annual Meeting